A powerpoint about the issue revolving around marijuana use and legalization. More specifically about how it effects the economy and people when you legalize it's recreational use, but classify it as an illicit drug in drug tests.
Substance abuse in the workplace ppt (sflpp version)oliviaenny
This document outlines a state loss prevention program on substance abuse in the workplace. It discusses the scope and costs of substance abuse, how alcohol and drugs impair job performance, and how to recognize substance abuse problems. It also covers company policies on substance abuse, including prohibiting drug and alcohol possession and being under the influence at work. The document encourages understanding substance abuse risks, getting help for problems, and addressing issues promptly to maintain workplace safety and productivity.
This webinar will provide an overview of current FDA regulation of pharmacy compounding in the wake of the 2012 meningitis outbreak. It will discuss the legislative efforts taken by Congress to clarify the FDA's authority over compounding pharmacies. The webinar will cover the FDA's traditional approach to regulating compounding, its current policy statement, recent enforcement trends, and two pieces of pending legislation - HR 3089 and HR 3204. Pharmacists, pharmacy technicians, and those in regulatory affairs and quality control in the pharmaceutical industry would benefit from attending.
Cannabis Science & Policy Summit - Day 2 - NovakCannabisSummit
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
A study conducted by Asante Pharmacy found that their controlled substance screening policy, developed based on guidance from the DEA and Oregon's Prescription Drug Monitoring Program, significantly reduced problematic opioid use among patients. The policy screening each prescription led to decreases of 16% in daily morphine doses over 120mg, 33% in maximum daily methadone doses over 40mg, and reductions in patients receiving drugs from multiple prescribers or pharmacies. The federal and state efforts were initiated in response to rising prescription drug abuse and overdose deaths.
Cannabis Science & Policy Summit - Day 1 - CaulkinsCannabisSummit
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
This document discusses ethics in the pharmaceutical industry. It provides examples of unethical behavior by pharmaceutical companies, such as experiments on human subjects without proper consent and misleading drug advertisements. It also outlines ethical behaviors like integrity, transparency, and prioritizing patient care. The core issues discussed are balancing profit motives with medical research and treatment goals. International regulatory bodies aim to promote ethical standards and enforce codes of conduct.
Three large employee assistance programs (EAPs) - Aetna, OptumHealth, and ValueOptions - piloted adding screening and brief intervention protocols for risky drinking to their services. This led to identifying 50-100% more employees with alcohol issues. Aetna identified risky drinking in 40% of clients screened and increased clinical follow-ups. OptumHealth identified risky drinking in 20.1% of clients compared to 7.5% previously and increased referrals to treatment. ValueOptions screened over 3,000 people and identified risky drinking in 7% leading to further screening, where 12% were found to have elevated risk.
Substance abuse in the workplace ppt (sflpp version)oliviaenny
This document outlines a state loss prevention program on substance abuse in the workplace. It discusses the scope and costs of substance abuse, how alcohol and drugs impair job performance, and how to recognize substance abuse problems. It also covers company policies on substance abuse, including prohibiting drug and alcohol possession and being under the influence at work. The document encourages understanding substance abuse risks, getting help for problems, and addressing issues promptly to maintain workplace safety and productivity.
This webinar will provide an overview of current FDA regulation of pharmacy compounding in the wake of the 2012 meningitis outbreak. It will discuss the legislative efforts taken by Congress to clarify the FDA's authority over compounding pharmacies. The webinar will cover the FDA's traditional approach to regulating compounding, its current policy statement, recent enforcement trends, and two pieces of pending legislation - HR 3089 and HR 3204. Pharmacists, pharmacy technicians, and those in regulatory affairs and quality control in the pharmaceutical industry would benefit from attending.
Cannabis Science & Policy Summit - Day 2 - NovakCannabisSummit
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
A study conducted by Asante Pharmacy found that their controlled substance screening policy, developed based on guidance from the DEA and Oregon's Prescription Drug Monitoring Program, significantly reduced problematic opioid use among patients. The policy screening each prescription led to decreases of 16% in daily morphine doses over 120mg, 33% in maximum daily methadone doses over 40mg, and reductions in patients receiving drugs from multiple prescribers or pharmacies. The federal and state efforts were initiated in response to rising prescription drug abuse and overdose deaths.
Cannabis Science & Policy Summit - Day 1 - CaulkinsCannabisSummit
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
This document discusses ethics in the pharmaceutical industry. It provides examples of unethical behavior by pharmaceutical companies, such as experiments on human subjects without proper consent and misleading drug advertisements. It also outlines ethical behaviors like integrity, transparency, and prioritizing patient care. The core issues discussed are balancing profit motives with medical research and treatment goals. International regulatory bodies aim to promote ethical standards and enforce codes of conduct.
Three large employee assistance programs (EAPs) - Aetna, OptumHealth, and ValueOptions - piloted adding screening and brief intervention protocols for risky drinking to their services. This led to identifying 50-100% more employees with alcohol issues. Aetna identified risky drinking in 40% of clients screened and increased clinical follow-ups. OptumHealth identified risky drinking in 20.1% of clients compared to 7.5% previously and increased referrals to treatment. ValueOptions screened over 3,000 people and identified risky drinking in 7% leading to further screening, where 12% were found to have elevated risk.
Cannabis Science & Policy Summit - Day 1 - KaganCannabisSummit
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - WetterauCannabisSummit
1. ASAM supports decriminalizing marijuana possession for personal use and treating it as a civil offense linked to contingencies like mandated clinical assessment and treatment.
2. ASAM does not support legalizing marijuana and recommends caution in jurisdictions that have not legalized it yet until more is learned from places that have.
3. The document outlines several recommendations from ASAM for regulating legalized recreational marijuana and expanding access to treatment and prevention services for marijuana use, especially among youth.
This document summarizes a presentation given by Demetra Ashley of the DEA about regulations and efforts to address the prescription drug abuse epidemic. It discusses how most prescription drug abuse involves obtaining medications from friends and family, not through criminal means. The DEA works with various groups to educate on responsible prescribing and dispensing through initiatives like take-back events and conferences. The goal is to curb abuse while ensuring access to needed medications through enforcement as well as prevention and treatment efforts.
Cannabis Science & Policy Summit - Day 1 - HallCannabisSummit
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
This document discusses the benefits of creating a healthy work environment free of substance abuse. It provides data showing that alcohol, tobacco, and drug use increases healthcare costs and reduces productivity through absenteeism and accidents. Employers can realize cost savings through education programs, cessation services, and policies that support treatment and recovery. The document recommends steps for employers like establishing employee assistance programs, adopting comprehensive substance abuse policies, and ensuring health plans provide treatment coverage.
Safe prescribing Practices Conference for Medical Professionals june 2013Heidi Denton
Participants will:
Report their intent to support and/or actively work towards incorporating best practices in responsible prescribing guidelines into their everyday practice of medicine.
Report an increased knowledge of the Michigan Automated Prescription System (MAPS) and the benefits of reporting regularly to MAPS.
Report intent to support and/or actively work towards incorporating consistent use of the MAPS into their everyday practice of prescribing controlled substances.
Report that at the training they received easy to use tools that can help them to better educate their patients on the importance of taking medications as prescribed.
Gain an increased knowledge of local, state, and national substance abuse and mental health treatment resources.
Dealing with Substance Abuse in the WorkplaceCase IQ
Security expert Timothy Dimoff discusses tips for dealing with substance abuse in the workplace. To view the webinar recording, visit: http://i-sight.com/webinar-substance-abuse-in-the-workplace/
Cannabis Science & Policy Summit - Day 1 - SeiverightCannabisSummit
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
This document discusses safety concerns regarding the class of antibiotics known as fluoroquinolones. It notes that while common side effects were established when these drugs were approved decades ago, more serious side effects affecting mental health and blood sugar levels have been recognized more recently based on expanded data. The document expresses concern that fluoroquinolone use is irrationally high in Pakistan compared to other countries, and serious side effects are underreported. It argues this indicates weaknesses in Pakistan's regulatory system that prioritize economic interests over patient safety. Recent actions by the FDA to strengthen fluoroquinolone labels are also summarized.
Cannabis Science & Policy Summit - Day 1 - CruzCannabisSummit
This document summarizes research on cannabis legalization in Uruguay. It discusses four areas of focus: public opinion analysis, impact on frequent consumers, cannabis clubs, and retail distribution. The presentation specifically discusses national surveys showing most Uruguayans initially disagreed with legalization but viewed medical cannabis and state intervention favorably, though many felt use had increased. However, data on use was inconsistent. Implementation of the cannabis law faces challenges of general disapproval, concerns over pharmacy distribution, and needs better communication and prevention strategies.
Cannabis Science & Policy Summit - Day 1 - PeyraubeCannabisSummit
Uruguay has reformed its drug policy based on a framework of security, public health, and human rights. It prioritizes human rights conventions and national sovereignty over international drug conventions. Uruguay regulates cannabis to reduce the negative impacts of drugs and incarceration for possession. The regulation creates a domestic cannabis industry and allows medical use and research. Adults can access cannabis through self-cultivation, cannabis clubs, or purchasing up to 40 grams per month from pharmacies. Production is licensed and regulated by the government.
Cannabis Science & Policy Summit - Day 1 - SabetCannabisSummit
This document discusses alternatives to legalizing marijuana that were presented in a RAND report on Vermont. It notes that most of the options presented in the RAND report were still versions of legalization, and that there are other models that do not involve legalizing marijuana. These include civil citation programs that require drug assessment, community service, and interventions for first-time offenders, diversion programs requiring drug education or treatment, and decriminalization laws requiring drug education or treatment following an offense. The document provides examples of such programs in Florida, New Jersey, Maryland, and Maryland's decriminalization law.
Marijuana, Opioids and State Laws – What HR Teams Need to KnowCareerBuilder
This document summarizes a presentation on workplace drug testing and compliance issues. It discusses evolving issues in the drug testing industry, including medical marijuana and prescription drug laws. It provides an overview of federal laws and how they differ from varying state laws on these topics. Key court cases are mentioned, and employers' obligations under the ADA regarding prescription drug testing are reviewed. Challenges for employers around the opioid epidemic are also examined. State-specific compliance rules for drug testing programs are outlined.
This document summarizes a panel discussion on improving utilization of prescription drug monitoring programs (PDMPs). The panel will discuss current practices for interstate sharing of PDMP data, strategies for integrating PDMP data into healthcare records, and lessons from Washington state's program providing organizations access to PDMP data. The goal is to identify best practices that can be implemented in other states to increase interoperability and utilization of PDMP data.
This document discusses ensuring access to quality substance use disorder (SUD) treatment. It outlines federal laws like the Mental Health Parity and Addiction Equity Act and Affordable Care Act that are intended to improve access to SUD treatment. It also discusses some state parity laws. While progress has been made in expanding coverage for SUD treatment, barriers still exist like limits on services and lack of providers. Enforcement of these laws is needed to fully achieve parity and reduce denials of medically necessary care.
AIM Target Programs is the leader in out-patient counseling and assessment, providing services for substance abuse, drug testing, BIP/domestic violence, anger management, and anti-theft. Incorporated in 1994, AIM Target has been helping adult residents of Southwest Florida for over 22 years with over 67,000 people served.
Cannabis Science & Policy Summit - Day 2 - OrensCannabisSummit
This document summarizes outcomes from the legalization of marijuana in Colorado over two years. Key findings include an increase in past month marijuana use prevalence and demand, with casual users accounting for more use. Prices have decreased while concentrate sales have risen. Legalization has had a strong positive economic impact, creating thousands of jobs and over $1 billion in revenue. The regulated market now serves nearly three-quarters of total marijuana demand in Colorado.
This document outlines a conference for building cases across state lines related to pharmaceutical drug crimes. It discusses the roles of various practitioners, authorities, investigators and prosecutors involved in these types of cases. It also covers the evolution of the prescription drug epidemic and how prescription drug monitoring programs can aid in multi-state investigations. The document identifies common roadblocks to effective multi-state investigations and the prosecutor's role in working with investigators during early case development.
This survey by the Society for Human Resource Management examined policies related to marijuana use in the workplace in states that have legalized medical and/or recreational marijuana use. The key findings were:
1) The vast majority (94%) of organizations surveyed had a formal substance use policy, with policies specifically addressing marijuana use more common where it was legalized for both medical and recreational use.
2) Most organizations (73-82%) had a zero-tolerance policy prohibiting marijuana use while working.
3) Common disciplinary actions for first violations included termination (41-50%), mandatory drug counseling (16-21%), and written warnings (14-19%).
4) Around half of organizations conducted pre-employment
On Tuesday, March 8, 2022 Kegler Brown presented its annual Managing Labor + Employee Seminar. The virtual seminar focused on timely information regarding labor and employee relations, and allowed attendees to earn CLE and SHRM credit hours.
Cannabis Science & Policy Summit - Day 1 - KaganCannabisSummit
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - WetterauCannabisSummit
1. ASAM supports decriminalizing marijuana possession for personal use and treating it as a civil offense linked to contingencies like mandated clinical assessment and treatment.
2. ASAM does not support legalizing marijuana and recommends caution in jurisdictions that have not legalized it yet until more is learned from places that have.
3. The document outlines several recommendations from ASAM for regulating legalized recreational marijuana and expanding access to treatment and prevention services for marijuana use, especially among youth.
This document summarizes a presentation given by Demetra Ashley of the DEA about regulations and efforts to address the prescription drug abuse epidemic. It discusses how most prescription drug abuse involves obtaining medications from friends and family, not through criminal means. The DEA works with various groups to educate on responsible prescribing and dispensing through initiatives like take-back events and conferences. The goal is to curb abuse while ensuring access to needed medications through enforcement as well as prevention and treatment efforts.
Cannabis Science & Policy Summit - Day 1 - HallCannabisSummit
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
This document discusses the benefits of creating a healthy work environment free of substance abuse. It provides data showing that alcohol, tobacco, and drug use increases healthcare costs and reduces productivity through absenteeism and accidents. Employers can realize cost savings through education programs, cessation services, and policies that support treatment and recovery. The document recommends steps for employers like establishing employee assistance programs, adopting comprehensive substance abuse policies, and ensuring health plans provide treatment coverage.
Safe prescribing Practices Conference for Medical Professionals june 2013Heidi Denton
Participants will:
Report their intent to support and/or actively work towards incorporating best practices in responsible prescribing guidelines into their everyday practice of medicine.
Report an increased knowledge of the Michigan Automated Prescription System (MAPS) and the benefits of reporting regularly to MAPS.
Report intent to support and/or actively work towards incorporating consistent use of the MAPS into their everyday practice of prescribing controlled substances.
Report that at the training they received easy to use tools that can help them to better educate their patients on the importance of taking medications as prescribed.
Gain an increased knowledge of local, state, and national substance abuse and mental health treatment resources.
Dealing with Substance Abuse in the WorkplaceCase IQ
Security expert Timothy Dimoff discusses tips for dealing with substance abuse in the workplace. To view the webinar recording, visit: http://i-sight.com/webinar-substance-abuse-in-the-workplace/
Cannabis Science & Policy Summit - Day 1 - SeiverightCannabisSummit
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
This document discusses safety concerns regarding the class of antibiotics known as fluoroquinolones. It notes that while common side effects were established when these drugs were approved decades ago, more serious side effects affecting mental health and blood sugar levels have been recognized more recently based on expanded data. The document expresses concern that fluoroquinolone use is irrationally high in Pakistan compared to other countries, and serious side effects are underreported. It argues this indicates weaknesses in Pakistan's regulatory system that prioritize economic interests over patient safety. Recent actions by the FDA to strengthen fluoroquinolone labels are also summarized.
Cannabis Science & Policy Summit - Day 1 - CruzCannabisSummit
This document summarizes research on cannabis legalization in Uruguay. It discusses four areas of focus: public opinion analysis, impact on frequent consumers, cannabis clubs, and retail distribution. The presentation specifically discusses national surveys showing most Uruguayans initially disagreed with legalization but viewed medical cannabis and state intervention favorably, though many felt use had increased. However, data on use was inconsistent. Implementation of the cannabis law faces challenges of general disapproval, concerns over pharmacy distribution, and needs better communication and prevention strategies.
Cannabis Science & Policy Summit - Day 1 - PeyraubeCannabisSummit
Uruguay has reformed its drug policy based on a framework of security, public health, and human rights. It prioritizes human rights conventions and national sovereignty over international drug conventions. Uruguay regulates cannabis to reduce the negative impacts of drugs and incarceration for possession. The regulation creates a domestic cannabis industry and allows medical use and research. Adults can access cannabis through self-cultivation, cannabis clubs, or purchasing up to 40 grams per month from pharmacies. Production is licensed and regulated by the government.
Cannabis Science & Policy Summit - Day 1 - SabetCannabisSummit
This document discusses alternatives to legalizing marijuana that were presented in a RAND report on Vermont. It notes that most of the options presented in the RAND report were still versions of legalization, and that there are other models that do not involve legalizing marijuana. These include civil citation programs that require drug assessment, community service, and interventions for first-time offenders, diversion programs requiring drug education or treatment, and decriminalization laws requiring drug education or treatment following an offense. The document provides examples of such programs in Florida, New Jersey, Maryland, and Maryland's decriminalization law.
Marijuana, Opioids and State Laws – What HR Teams Need to KnowCareerBuilder
This document summarizes a presentation on workplace drug testing and compliance issues. It discusses evolving issues in the drug testing industry, including medical marijuana and prescription drug laws. It provides an overview of federal laws and how they differ from varying state laws on these topics. Key court cases are mentioned, and employers' obligations under the ADA regarding prescription drug testing are reviewed. Challenges for employers around the opioid epidemic are also examined. State-specific compliance rules for drug testing programs are outlined.
This document summarizes a panel discussion on improving utilization of prescription drug monitoring programs (PDMPs). The panel will discuss current practices for interstate sharing of PDMP data, strategies for integrating PDMP data into healthcare records, and lessons from Washington state's program providing organizations access to PDMP data. The goal is to identify best practices that can be implemented in other states to increase interoperability and utilization of PDMP data.
This document discusses ensuring access to quality substance use disorder (SUD) treatment. It outlines federal laws like the Mental Health Parity and Addiction Equity Act and Affordable Care Act that are intended to improve access to SUD treatment. It also discusses some state parity laws. While progress has been made in expanding coverage for SUD treatment, barriers still exist like limits on services and lack of providers. Enforcement of these laws is needed to fully achieve parity and reduce denials of medically necessary care.
AIM Target Programs is the leader in out-patient counseling and assessment, providing services for substance abuse, drug testing, BIP/domestic violence, anger management, and anti-theft. Incorporated in 1994, AIM Target has been helping adult residents of Southwest Florida for over 22 years with over 67,000 people served.
Cannabis Science & Policy Summit - Day 2 - OrensCannabisSummit
This document summarizes outcomes from the legalization of marijuana in Colorado over two years. Key findings include an increase in past month marijuana use prevalence and demand, with casual users accounting for more use. Prices have decreased while concentrate sales have risen. Legalization has had a strong positive economic impact, creating thousands of jobs and over $1 billion in revenue. The regulated market now serves nearly three-quarters of total marijuana demand in Colorado.
This document outlines a conference for building cases across state lines related to pharmaceutical drug crimes. It discusses the roles of various practitioners, authorities, investigators and prosecutors involved in these types of cases. It also covers the evolution of the prescription drug epidemic and how prescription drug monitoring programs can aid in multi-state investigations. The document identifies common roadblocks to effective multi-state investigations and the prosecutor's role in working with investigators during early case development.
This survey by the Society for Human Resource Management examined policies related to marijuana use in the workplace in states that have legalized medical and/or recreational marijuana use. The key findings were:
1) The vast majority (94%) of organizations surveyed had a formal substance use policy, with policies specifically addressing marijuana use more common where it was legalized for both medical and recreational use.
2) Most organizations (73-82%) had a zero-tolerance policy prohibiting marijuana use while working.
3) Common disciplinary actions for first violations included termination (41-50%), mandatory drug counseling (16-21%), and written warnings (14-19%).
4) Around half of organizations conducted pre-employment
On Tuesday, March 8, 2022 Kegler Brown presented its annual Managing Labor + Employee Seminar. The virtual seminar focused on timely information regarding labor and employee relations, and allowed attendees to earn CLE and SHRM credit hours.
Running Head FORMAL PAPER 2FORMAL PAPER 28(You did cove.docxcowinhelen
Running Head: FORMAL PAPER 2
FORMAL PAPER 2 8
(You did cover the topic, but some parts of your paper are hard to read. I made some corrections and comments (see the reference page). Your APA format for your references is not correct. You put the date you retrieved the information from the Internet. That is not done in the 6th edition of APA (minus 5 points). When you listed your states, you were not clear on whether the state had legalized marijuana or Charlotte's Web for medical or all purposes (minus 7 points). You also forgot to include the year it was legalized. The next step is to submit part three in a few weeks and when that is returned and all the corrections are made you will combine all three parts for the final paper. If you have any questions, contact me.)
Formal Paper Part 2
Amise Jean Francois
Professor Ray Lenius
Florida SouthWestern State College
March 4, 2018
There is much concern regarding the use of marijuana with some groups calling for its legalization because of its value, which is yet to be confirmed. On the other hand, others are of the opinion that marijuana is dangerous and there is no need for further investigation or research for the determination of its value. Marijuana exists it in two forms i.e.(e.g. regular marijuana used for the medical purposes and other functions as well the newly discovered strain called Cannabis or Charlotte's web) (Egan & Bane, 2014).
Regular marijuana has low tetrahydrocannabinol (THC), which is the dominant substance. Regular marijuana is an important medicine that is used for the treatment of glaucoma, chemotherapy, and multiple sclerosis. The presence of the low-tetrahydrocannabinol (THC) in the regular marijuana has been one of the reasons why some people have called for the ban on its use. Those opposing the use of the regular marijuana are of the argument that the value of the regular marijuana is being overrated (Egan & Bane, 2014).
On the other hand, Charlottes' web also known as a high-cannabidiol (CBD) tends to be more effective when compared to the low tetrahydrocannabinol (THC) when used as medicine. This is because it has a high cannabidiol (CBD) when compared to regular marijuana.despite Despite Charlotte's web having low tetrahydrocannabinol (THC), it is the presence of the high cannabidiol that helps in the reduction of the paranoia as well as the anxiety. It also serves as the energy booster and antipsychotic.
Charlotte's web is essential for the treatment pain and the inflammation. Additionally, patients suffering from intestinal complications, epilepsy and bacterial infection find it ineffective to rely on Charlotte's web. Despite having 40 percent concentration of high cannabidiol, Charlotte's web is lacking importance, highly demanding and desirable nutrients like amino acids, vitamins, and omega-3 (Hearing & Balducci, 2017). Despite having knowledge concerning the lack of these important elements in Charlotte's web, some have still gone ...
The Public Health Framework of LegalizedMarijuana in Colorad.docxoscars29
The Public Health Framework of Legalized
Marijuana in Colorado
Tista Ghosh, MD, MPH, Mike Van Dyke, PhD, Ali Maffey, MSW, Elizabeth Whitley, RN, PhD, Laura Gillim-Ross, PhD, and
Larry Wolk, MD, MSPH
On January 1, 2014, Colorado became the first state in the nation to sell legal rec-
reational marijuana for adult use. As a result, Colorado has had to carefully examine
potential population health and safety impacts as well as the role of public health in
response to legalization. We have discussed an emerging public health framework for
legalized recreational marijuana. We have outlined this framework according to the core
public health functions of assessment, policy development, and assurance. In addition,
we have discussed challenges to implementing this framework that other states con-
sidering legalization may face. (Am J Public Health. 2016;106:21–27. doi:10.2105/
AJPH.2015.302875)
As one of the first 2 states to legalize rec-reational (nonmedical) marijuana, Col-
orado has been compelled to carefully examine
potential impacts to the health and safety of the
public. Medical marijuana has been legal in
Colorado since 2000, and marijuana use was
initially viewed as an individual patient–doctor
decision that was outside the scope of
population-based surveillance and public
health policy. This view began to changewhen
the commercial production and distribution of
medical marijuana becamepermissiblein2009.
However, it was the legalization of marijuana
for adult nonmedical use in late 2012 that
prompted a closer examination of marijuana’s
potential public health impact.
On January 1, 2014, Colorado became the
first state in the nation to allow sales of rec-
reational marijuana. The current legal status of
marijuana has compelled the Colorado De-
partment of Public Health and Environment
(referred to as the department hereafter) to
assess the knowledge gaps related to marijuana
and develop reasonable policies to protect
vulnerable populations. This “social experi-
ment”hasfurtherrequiredColoradotodefine
core public health functions as they pertain to
legalized recreational marijuana. In doing so,
the primary goals have been to implement
policies to mitigate potential harmful conse-
quences of legalized marijuana and to collect
the necessary data to measure possible nega-
tive and beneficial effects on the population.
Legalization has highlighted a broad set of
issues resulting from the multiple means of
marijuana use (e.g., smoking, edibles, con-
centrates), the lack of a mature regulatory
structure, and the complications of conflicting
state and federal marijuana laws. The breadth
of issues evolving from the legalization of
marijuana has compelled Colorado’s gov-
ernmental agencies to work collaboratively to
establish a retail sales system that respects the
intention of the voters while striving to
mitigate negative outcomes. With co-
ordination and direction from the Governor’s
Office of Marijuana Coordination, experts
from a vari.
Discuss the complexities of presenting highly technical findings (.docxstandfordabbot
Discuss the complexities of presenting highly technical findings (e.g., Wireshark) to non-technical management. How would you present the information and take action?
Discuss the complexities of presenting highly technical findings
(e.g., Wireshark) to non
-
technical management.
How would you present the information and take action?
Discuss the complexities of presenting highly technical findings (e.g., Wireshark) to non-technical management.
How would you present the information and take action?
The Public Health Framework of Legalized
Marijuana in Colorado
Tista Ghosh, MD, MPH, Mike Van Dyke, PhD, Ali Maffey, MSW, Elizabeth Whitley, RN, PhD, Laura Gillim-Ross, PhD, and
Larry Wolk, MD, MSPH
On January 1, 2014, Colorado became the first state in the nation to sell legal rec-
reational marijuana for adult use. As a result, Colorado has had to carefully examine
potential population health and safety impacts as well as the role of public health in
response to legalization. We have discussed an emerging public health framework for
legalized recreational marijuana. We have outlined this framework according to the core
public health functions of assessment, policy development, and assurance. In addition,
we have discussed challenges to implementing this framework that other states con-
sidering legalization may face. (Am J Public Health. 2016;106:21–27. doi:10.2105/
AJPH.2015.302875)
As one of the first 2 states to legalize rec-reational (nonmedical) marijuana, Col-
orado has been compelled to carefully examine
potential impacts to the health and safety of the
public. Medical marijuana has been legal in
Colorado since 2000, and marijuana use was
initially viewed as an individual patient–doctor
decision that was outside the scope of
population-based surveillance and public
health policy. This view began to changewhen
the commercial production and distribution of
medical marijuana becamepermissiblein2009.
However, it was the legalization of marijuana
for adult nonmedical use in late 2012 that
prompted a closer examination of marijuana’s
potential public health impact.
On January 1, 2014, Colorado became the
first state in the nation to allow sales of rec-
reational marijuana. The current legal status of
marijuana has compelled the Colorado De-
partment of Public Health and Environment
(referred to as the department hereafter) to
assess the knowledge gaps related to marijuana
and develop reasonable policies to protect
vulnerable populations. This “social experi-
ment”hasfurtherrequiredColoradotodefine
core public health functions as they pertain to
legalized recreational marijuana. In doing so,
the primary goals have been to implement
policies to mitigate potential harmful conse-
quences of legalized marijuana and to collect
the necessary data to measure possible nega-
tive and beneficial effects on the population.
Legalization has highlighted a broad set of
issues resulting from the multiple means of
marijuana use (e.g., smokin.
The document discusses various aspects of cannabis/marijuana including:
- Its botanical classification as Cannabis sativa and the two most dominant cannabinoids, THC and CBD.
- Differences between hemp and marijuana in terms of THC content and approved uses.
- Issues around employers requiring drug testing and being able to take action against employees who use medical marijuana, even if legal in their state.
- The complex interplay between state medical marijuana laws and federal laws where marijuana remains illegal.
The document discusses drug testing in the workplace. It provides background on the rise of drug testing programs in American firms since the 1980s as a way to detect and address substance abuse issues. It then covers various aspects of drug testing including definitions of drugs, trends in drug testing, the perceived pros and cons of workplace drug testing programs, specifics of drug testing methods and what can be tested, factors that can impact drug test results, and common drug detection periods. It also briefly outlines drug testing practices by different industries.
Unauthorised and unregulated drugs lacking generic identities have flooded the local market through misleading advertising campaigns. These drugs are prescribed by some doctors in large quantities without knowing their effects. Loophole in laws allow import of herbal concoctions falsely labeled as drugs. Stricter implementation of National Drugs Policy is needed to regulate drug importation, distribution and sales. Random quality checks and making importers liable for failed batches can improve screening of imported drugs. Patients' rights include being informed of treatment risks and alternatives to expensive brands lacking proven benefits.
This document summarizes a presentation on data-driven trends related to prescription drug abuse. It outlines national trends in doctor shopping, overdoses, drugged driving, and opioid/heroin overdose deaths. It also evaluates the effectiveness of some state laws and programs aimed at reducing doctor shopping and responding to overdoses. Some promising policy strategies discussed include reducing inappropriate prescribing, focusing on overdose response, improving prescription drug monitoring programs, and linking overdose victims to treatment.
This document summarizes a presentation on building local capacity to prevent prescription drug abuse. It discusses three panelists who will speak on approaches to prevent Rx drug misuse, abuse, and diversion. These include Terry Cline, Commissioner of Health for Oklahoma; Gregg Raduka, Director of Prevention/Intervention for The Council on Alcohol and Drugs; and Christopher Wood from the Georgia Department of Behavioral Health and Developmental Disabilities. The moderator will be Regina LaBelle from the White House Office of National Drug Control Policy. The panelists will discuss policy and program approaches, the role of state health agencies in collaborating with partners, and how to form and engage statewide Rx prevention collaboratives.
This document discusses the history of drug regulation laws in the United States. It begins by covering early federal laws like the 1906 Pure Food and Drug Act that required labeling of drug contents but did little to regulate safety. The 1938 Food, Drug, and Cosmetic Act and later amendments in 1951 and 1962 strengthened regulations by requiring pre-market approval of drugs as safe and effective. The Controlled Substances Act of 1970 established a drug scheduling system to regulate substances based on abuse and medical potential. The document also discusses issues around legalization debates, prevention strategies, drug testing policies, and criticisms of discriminatory enforcement practices.
Webinar: The Cost of Marijuana in the WorkplaceLucas Kibby
Industry expert Lukas Shaw will be covering what the current political environment is around marijuana, how it affects your body, what are the benefits of a drug testing program, and discuss what can or should companies do today in the workplace regarding marijuana.
Safe Prescribing DEA and controlled drugs essay.docxwrite4
The document discusses safe prescribing of controlled substances by PMHNPs. It covers:
1) The role of the DEA is to control illegal narcotics and ensure prescription/supply of controlled drugs is done by licensed professionals with DEA numbers.
2) Possessing a DEA number shows competency in prescribing controlled drugs and carries responsibilities of adhering to federal laws regarding prescription, manufacturing and distribution.
3) To acquire a DEA number, a person must fill out an application form on the DEA website or in person, then wait 3 days to receive approval or pending status.
The document outlines state responses to prescription drug and heroin abuse presented at an advocacy track session. It includes presentations from officials in Arizona, Virginia, and New Mexico on their state's strategies. Arizona's presentation focuses on the state's prescriber report cards. Virginia's presentation discusses the governor's task force recommendations and a new health and criminal justice data committee. New Mexico's presentation describes the state's high overdose rates and model of stakeholder collaboration to reduce overdose deaths.
This document provides a policy recommendation for the State of Colorado regarding grey market practices in the state's medical and recreational marijuana markets. It conducted interviews with stakeholders and examined local regulations and policies. The document finds that the disparity in tax rates between the medical and recreational markets has led to a growth in the grey market. It recommends two policy options: adopting Fort Collins' regulatory approach or tightening regulations for caregivers to close loopholes and curtail grey market activity. Adopting either of these recommendations could help fuse the two marijuana markets and reduce illicit practices.
Watch this expert-led webinar to learn effective tactics that high-volume hiring teams can use right now to attract top talent into their pipeline faster.
How to Leverage AI to Boost Employee Wellness - Lydia Di Francesco - SocialHR...SocialHRCamp
Speaker: Lydia Di Francesco
In this workshop, participants will delve into the realm of AI and its profound potential to revolutionize employee wellness initiatives. From stress management to fostering work-life harmony, AI offers a myriad of innovative tools and strategies that can significantly enhance the wellbeing of employees in any organization. Attendees will learn how to effectively leverage AI technologies to cultivate a healthier, happier, and more productive workforce. Whether it's utilizing AI-powered chatbots for mental health support, implementing data analytics to identify internal, systemic risk factors, or deploying personalized wellness apps, this workshop will equip participants with actionable insights and best practices to harness the power of AI for boosting employee wellness. Join us and discover how AI can be a strategic partner towards a culture of wellbeing and resilience in the workplace.
AI Considerations in HR Governance - Shahzad Khan - SocialHRCamp Ottawa 2024SocialHRCamp
Speaker: Shahzad Khan
This session on "AI Considerations in Human Resources Governance" explores the integration of Artificial Intelligence (AI) into HR practices, examining its history, current applications, and the governance issues it raises. A framework to view Government in modern organizations is provided, along with the transformation and key considerations associated with each element of this framework, drawing lessons from other AI projects to illustrate these aspects. We then dive into AI's use in resume screening, talent acquisition, employee retention, and predictive analytics for workforce management. Highlighting modern governance challenges, it addresses AI's impact on the gig economy as well as DEI. We then conclude with future trends in AI for HR, offering strategic recommendations for incorporating AI in HR governance.
Becoming Relentlessly Human-Centred in an AI World - Erin Patchell - SocialHR...SocialHRCamp
Speaker: Erin Patchell
Imagine a world where the needs, experiences, and well-being of people— employees and customers — are the focus of integrating technology into our businesses. As HR professionals, what tools exist to leverage AI and technology as a force for both people and profit? How do we influence a culture that takes a human-centred lens?
Building Meaningful Talent Communities with AI - Heather Pysklywec - SocialHR...SocialHRCamp
Speaker: Heather Pysklywec
Digital transformation has transformed the talent acquisition landscape over the past ten years. Now, with the introduction of artificial intelligence, HR professionals are faced with a new suite of tools to choose from. The question remains, where to start, what to be aware of, and what tools will complement the talent acquisition strategy of the organization? This session will give a summary of helpful AI tools in the industry, explain how they can fit into existing systems, and encourage attendees to explore if AI tools can improve their process.
Accelerating AI Integration with Collaborative Learning - Kinga Petrovai - So...SocialHRCamp
Speaker: Kinga Petrovai
You have the new AI tools, but how can you help your team use them to their full potential? As technology is changing daily, it’s hard to learn and keep up with the latest developments. Help your team amplify their learning with a new collaborative learning approach called the Learning Hive.
This session outlines the Learning Hive approach that sets up collaborations that foster great learning without the need for L&D to produce content. The Learning Hive enables effective knowledge sharing where employees learn from each other and apply this learning to their work, all while building stronger community bonds. This approach amplifies the impact of other learning resources and fosters a culture of continuous learning within the organization.
Your Guide To Finding The Perfect Part-Time JobSnapJob
Part-time workers account for a significant part of the workforce, including individuals of all ages. A lot of industries hire part-time workers in different capacities, including temporary or seasonal openings, ranging from managerial to entry-level positions. However, many people still doubt taking on these roles and wonder how a temporary part-time job can help them achieve their long-term goals.
Start Smart: Learning the Ropes of AI for HR - Celine Maasland - SocialHRCamp...SocialHRCamp
Speaker: Celine Maasland
In this session, we’ll demystify the process of integrating artificial intelligence into everyday HR tasks. This presentation will guide HR professionals through the initial steps of identifying AI opportunities, choosing the right tools, and effectively implementing technology to streamline operations. Additionally, we’ll delve into the specialized skill of prompt engineering, demonstrating how to craft precise prompts to enhance interactions between AI systems and employees. Whether you’re new to AI or looking to refine some of your existing strategies, this session will equip you with the knowledge and tools to harness AI’s potential in transforming HR functions.
2. What is the issue?
The recreational use of marijuana is being legalized in states, however it is
still included as an illicit drug in drug tests
People are legally using marijuana but failing work place drug testing which is
restricting the work pool
There is consideration of government using drug testing before giving people
access to government aid services
The legalization of the drug is conflicting with drug tests because marijuana is
still considered an illicit drug in the drug testing policy
3. Potential Questions
Should marijuana be excluded from drug tests in states where it is no longer
an illicit drug?
What are the benefits of excluding marijuana from drug tests?
What are the cons of excluding marijuana from drug tests?
Are there specific places where it should not be excluded?
Does marijuana increase the risk of accidents?
4. Research Available
Websites that talk about workplace drug policies
Database articles on the effects of marijuana
Science/Health websites that discuss research done on marijuana users
Websites that list all the different places that enforce drug testing
6. Potential challenges
This is a very controversial topic because it involves the legalization of a drug
and excluding it from drug testing. Drug testing is important but the conflict
between having a drug that is legalized for recreational use by a state and
having it still be a part of drug testing is a tricky matter.
Finding statistics on problems involving marijuana is not as easy as alcohol
because alcohol can be legally obtained after a certain age in any state.
7. Why is the issue relevant?
There is an increasing number of people who are being declined work because
they live in states where marijuana has been legalized but according to drug
test policy it is still considered an illicit drug.
If drug tests are enforced by government programs then many people could
be denied aid for using a drug that is not considered dangerous.
The law and drug policy contradict each other and it is causing more
problems. More states are considering legalizing marijuana use, so the
problem will increase.